Overview
- Erasca priced an upsized public offering of 31,428,572 shares at $17.50 per share that is expected to raise about $550.0 million before fees, with the offering priced in filings on July 13–14 and an expected close on July 15, 2026.
- The company granted underwriters a 30-day option to buy up to 4,714,285 additional shares at the same price and filed a Form S-3 shelf registration plus a preliminary prospectus supplement with the SEC for the sale.
- Press reports of early phase 1 results for ERAS-0015 said the drug produced a 57 percent tumor reduction in a small pancreatic cancer cohort after eight weeks and showed encouraging signals with panitumumab, though the sample size is limited and results are preliminary.
- The clinical news and financing lifted the stock and prompted at least one analyst to raise its price target, and institutional interest appears to be growing as the company prepares combination and expansion data targeted for 2027.
- Erasca says net proceeds will fund R&D, development programs, working capital and general corporate needs, but investors should watch upcoming trial readouts and ongoing legal and safety matters cited in prior filings and third‑party reports as potential risks.